An Initiative by SAARTHI IAS
Polity & Governance

Draft Rules Tighten Antimicrobial Licensing

Drug Regulation, Antimicrobial Resistance New Drugs and Clinical Trials Rules, 2019, Drugs Rules, 1945
Share:
Draft Rules Tighten Antimicrobial Licensing - MaargX UPSC Current Affairs

Why in News?

  • The Union Health Ministry has issued two draft notifications that would tighten the licensing of antimicrobial medicines, according to details made public on 19 November 2026.
  • The drafts amend the New Drugs and Clinical Trials Rules, 2019 and the Drugs Rules, 1945.
  • Antimicrobials would count as a New Drug, so manufacturers would need prior permission from the Central Licensing Authority before applying to a State Licensing Authority.
  • The second draft would exempt makers of empty gelatin capsules, medicinal gases and disinfectant fluids from some provisions of the revised Schedule M.
  • The Ministry says the changes would neither dilute quality and safety standards nor weaken regulatory oversight.

Key Terminologies

Antimicrobial Resistance
The ability of bacteria, viruses, fungi and parasites to survive medicines that once killed them. It makes infections harder to treat and is a major global public health concern.
New Drug
A category under the New Drugs and Clinical Trials Rules, 2019 for medicines that need central approval before they are made or sold. Adding antimicrobials to it brings them under central scrutiny.
Central Licensing Authority
The central regulator that grants permissions for new drugs. Manufacturers would need its prior permission for antimicrobials before seeking a State licence.
Schedule M
Rules of good manufacturing practice for pharmaceutical plants under the Drugs Rules, 1945. The revised Schedule M sets higher standards, and the draft proposes limited exemptions for three product types.
One Health
An approach that links the health of people, animals and the environment. The G20 New Delhi Leaders' Declaration called for it in tackling antimicrobial resistance.

Key Issues

  • Weak Scrutiny at State Level: The draft follows concerns that antimicrobial manufacturing licences were granted without adequate checks such as bioavailability and bioequivalence and stability studies. Moving antimicrobials into the New Drug category adds a central check.
  • Dual Licensing: Manufacturers need prior permission from the Central Licensing Authority before approaching a State Licensing Authority. This blends central and State powers under the Drugs Rules, 1945.
  • Schedule M Flexibility: The Drugs Technical Advisory Board examined the matter at its 93rd meeting on 16 February and found that some revised Schedule M requirements may not suit empty gelatin capsules, medicinal gases and disinfectant fluids. Licensing authorities would decide product by product.
  • Aquaculture Blind Spot: A study of 460 papers and 11,274 bacterial isolates from 40 countries in Nature Communications in 2020 linked antimicrobial resistance in farmed fish with warmer water. In 2025-26 seven Indian shrimp consignments were rejected by the European Union and 12 by the United States for banned antibiotics.
  • Fragmented Regulation: Aquaculture oversight is split among the Coastal Aquaculture Authority, the Marine Products Export Development Authority, the Food Safety and Standards Authority of India and the Central Drugs Standard Control Organisation, and aquaculture is largely absent from national resistance plans, according to a World Antimicrobial Awareness Week analysis.

Key Implications

Positive/Pros/Merits

  • Stronger Safeguards: Central permission before State licensing can prevent weak or poorly studied antimicrobial products from reaching the market.
  • Public Health Link: The draft cites the G20 New Delhi Leaders' Declaration's call for a One Health approach, which links human, animal and environmental health.
  • Targeted Relief: The Schedule M exemptions respond to technical advice from the Drugs Technical Advisory Board and can reduce unnecessary compliance burden for products with different manufacturing processes.
  • Trade Credibility: Better control of antibiotic use supports export quality, since banned antibiotics have caused shrimp consignments to be rejected abroad.

Negative/Cons/Demerits

  • Possible Delays: An extra central approval step can lengthen licensing timelines for manufacturers, especially smaller firms.
  • Capacity Strain: The Central Licensing Authority will need staff and technical capacity to review many antimicrobial applications.
  • Exemption Risk: Any exemption from Schedule M needs careful monitoring so that quality does not slip, even though the Ministry says standards are not diluted.
  • Missing Details: The comment period and deadlines were not stated in the available details, which limits public consultation planning.

Key Initiatives

  • New Drugs and Clinical Trials Rules, 2019: The draft amends them to include antimicrobials in the definition of a New Drug.
  • Drugs Rules, 1945: The second draft proposes limited exemptions from the revised Schedule M for three product types, following advice of the Drugs Technical Advisory Board.
  • G20 New Delhi Leaders' Declaration: It called for a One Health approach to antimicrobial resistance, which the Ministry cites.
  • National Surveillance Programme for Aquatic Animal Diseases: It has confirmed 15 emerging and exotic aquatic animal diseases for the first time, and regulators have notified lists and formularies for aquaculture medicines.
Government's Current Approach

The Union Health Ministry says its aim is to strengthen scrutiny of antimicrobials while giving product-specific flexibility for certain low-risk products. It states that the draft rules would neither dilute quality and safety standards nor weaken regulatory oversight, and the proposals will go through consultation before they are finalised.

Director's Perspective

Way Forward

  • Publish the comment deadline and invite views from manufacturers, doctors and public health experts before finalising the rules.
  • Build central review capacity so that the new permission step does not delay genuine applications.
  • Extend the antimicrobial framework to veterinary and aquaculture use, in line with the One Health approach.
  • Publish product-specific Schedule M exemption decisions with reasons to maintain trust.
  • Strengthen surveillance of antibiotic residues in food and water, and of resistant infections in hospitals.
Key Takeaway

The draft rules strengthen oversight of antimicrobials at a time when resistance is a growing public health threat, and the Schedule M proposals show a risk-based approach. The weak points are possible licensing delays, thin central capacity and a regulatory gap in animal and aquaculture use. In a Mains answer, credit the central permission step and One Health link, then conclude that the rules will work only with strong enforcement, surveillance and coordination across regulators.

GS Relevance

GS Paper 2: Issues relating to the development and management of social sector and services relating to health, government policies and interventions, and regulatory bodies. GS Paper 3: Science and technology in everyday life and biotechnology.

Frequently Asked Questions

What do the draft antimicrobial rules propose?

The Union Health Ministry's draft notifications would include antimicrobials in the definition of a New Drug under the New Drugs and Clinical Trials Rules, 2019. Manufacturers would need prior permission from the Central Licensing Authority before applying to a State Licensing Authority for a licence.

Why is the Health Ministry tightening licensing of antimicrobials?

The Ministry cited concerns that antimicrobial manufacturing licences were granted without adequate scrutiny, including bioavailability, bioequivalence and stability studies. It also cited antimicrobial resistance as a major global health concern and the G20 New Delhi Leaders' Declaration's call for a One Health approach.

What is the Schedule M exemption in the draft?

The second draft proposes exemptions from some provisions of the revised Schedule M for makers of empty gelatin capsules, medicinal gases and disinfectant fluids. The Drugs Technical Advisory Board examined this at its 93rd meeting on 16 February, and the Ministry says standards will not be diluted.

PYQ Practice — Statement Analysis

1 The draft rules would treat antimicrobials as a New Drug under the New Drugs and Clinical Trials Rules, 2019.
True

Manufacturers would need prior permission from the Central Licensing Authority.

2 The draft Schedule M exemptions apply to all pharmaceutical manufacturers.
False

They are proposed for makers of empty gelatin capsules, medicinal gases and disinfectant fluids.

3 The G20 New Delhi Leaders' Declaration called for a One Health approach to antimicrobial resistance.
True

The Health Ministry cites this in the draft.

Share: